# Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

> **NCT05252988** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 177 (actual)

## Conditions studied

- Early-stage Breast Cancer
- HER2 Positive Breast Cancer
- Hormone Receptor Positive

## Interventions

- **DRUG:** Neratinib
- **DRUG:** Loperamide
- **DRUG:** Colesevelam

## Key facts

- **NCT ID:** NCT05252988
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-31
- **Primary completion:** 2024-10-28
- **Final completion:** 2030-01
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2025-04-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05252988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05252988, "Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05252988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*